psychiatric

Treatment with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for weight loss or diabetes management doesn ’t raise the risk for adverse psychiatric events and improves quality of life (QOL) in people with no history of mental illness, a large new review has found. The results, gleaned from placebo-controlled trials involving over 100,000 participants, are […]